Larson Financial Group LLC Sells 288 Shares of Zoetis Inc. (NYSE:ZTS)

Larson Financial Group LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 18.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,300 shares of the company’s stock after selling 288 shares during the quarter. Larson Financial Group LLC’s holdings in Zoetis were worth $212,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the 3rd quarter valued at about $31,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Asset Planning Inc bought a new position in shares of Zoetis during the 4th quarter valued at about $58,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $164.39 on Wednesday. The firm has a market cap of $73.61 billion, a P/E ratio of 30.05, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The business’s 50 day moving average price is $166.94 and its 200-day moving average price is $176.55. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 over the last ninety days. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ZTS shares. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Finally, Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.